It is a new internal FDA body for after-approval safety, not a new vaccine or therapy. The Food and Drug Administration announced the establishment of the CBER Safety Council, a governance group inside the Center for Biologics Evaluation and Research "dedicated to strengthening post-market safety oversight for products regulated by CBER, such as cell and gene therapies, vaccines and blood and blood products." FDA said the council is "an evolution from CBER's long-standing Safety Working Group" and that its establishment "is effective as of November 19, 2026." Additional details on structure, membership, and operating procedures "will be made available on the FDA's website," the announcement said.

The council "will be separate from the CBER product offices, reporting directly to the CBER Director," and is meant to give post-market safety work "a dedicated, cross-functional team with clear lines of accountability." By bringing together senior scientific and regulatory experts from across the center, FDA said, the council "provides a layer of review that is distinct from the product offices that conduct premarket approval," so that safety assessments supporting post-marketing actions are "comprehensive and consistent" and "the scientific evidence behind FDA's decisions is transparently communicated to the public."

FDA listed the council's duties: review and assess post-market safety signals across all CBER-regulated product categories; conduct structured benefit-risk assessments for regulatory-action recommendations; recommend actions to CBER leadership tied to Title IX of the Food and Drug Administration Amendments Act for safety reviews under Section 921, Safety Labeling Changes, Risk Evaluation and Mitigation Strategies, and safety-related Postmarketing Requirements; recommend safety-related market withdrawals; and recommend actions on Post-Approval Studies required in a Premarket Approval order or regulation for class III devices, and on Postmarketing Surveillance Studies required under section 522 of the FD&C Act for certain class II or class III devices. It will also "publish public-facing safety communications promptly after significant safety determinations" and coordinate with the CDC, NIH, and international regulators.

The council "will be managed by the Senior Advisor for Postmarketing Safety, who will report directly to the CBER Director," and will draw on the Division of Pharmacovigilance, the CBER Surveillance Program, and the Division of Analytics and Benefit-Risk Assessment. FDA said it will keep formal surveillance partnerships with the Sentinel System, VAERS, and the CDC Vaccine Safety Datalink. The council "may recommend regulatory actions to the Center Director, who remains responsible for appropriate regulatory actions."

This is a change in how CBER organizes post-market review, not a recall and not an approval or withdrawal of any named product. FDA encouraged manufacturers, clinicians, and patient advocates to keep reporting adverse events through existing channels, including VAERS and MedWatch. The announcement did not list council members or a first meeting date; those details, FDA said, are still to come on the agency's website.